BTIG lowered the firm’s price target on OrthoPediatrics (KIDS) to $38 from $44 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in the MedTech space. The sector had been seen as a safe haven, but quarterly results will matter less than a company’s ability to navigate ahead, the analyst tells investors in a research note. Between a frenetic trade war largely now directed at China to cuts at many federal healthcare agencies, investors will want answers which companies may not be able to provide, and this may weigh on sentiment, the firm adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics price target lowered to $24 from $26 at Truist
- OrthoPediatrics: Strategic Expansion and Risk Mitigation Justify Buy Rating
- OrthoPediatrics announces U.S. launch of VerteGlide Spinal Growth Guidance
- OrthoPediatrics: Strategic Niche and Growth Potential Justify Buy Rating
- OrthoPediatrics initiated with a Buy at Lake Street